Nektar Therapeutics Cash Flow - Annual (NASDAQ:NKTR)

Add to My Stocks
$22.53 $0.36 (1.57%) NKTR stock closing price Mar 23, 2017 (Closing)

The financial analysis of NKTR requires an investor to check the cash flows for Nektar Therapeutics. In simple terms, the cash flow statement measures the cash that has come into the company, and the cash that has gone out during a given period, while the other statements, the income statement and balance sheet, give details about Nektar Therapeutics profits and Nektar Therapeutics debt. Nektar Therapeutics cash flow analysis is possible because this statement breaks down how balance sheet accounts and income statement items affect cash and cash equivalents.  Nektar Therapeutics had cash and cash equivalents of $12.36M at the beginning of the year and $55.57M at year end for 2015.   Nektar Therapeutics has a positive cash and cash equivalents change of $43.2M. View details of Nektar Therapeutics cash flows for latest & last ten financial years.

show more
Annual
Quarterly
View Previous Years
View Next Years
Fiscal year is Jan - Dec. 2015 2014 2013 2012 2011 2010 2009 2008 2007
Nektar Therapeutics Net Income Cash Flow
-81.17M-53.91M-162.01M-171.85M-133.97M-37.93M-102.51M-34.33M-32.76M
Depreciation Depletion Amortization Cash-Flow12.85M12.92M14.27M14.5M14.95M16.55M14.88M22.48M28.15M
Net Increase (Decrease) in Assets Liabilities-34.7M-116.42M90.58M1.6M-14.95M-64.65M117.7M-26.79M106.75M
Cash From (used in) Discontinued Operations---------
Other Adjustments Net29.94M15.4M18.62M25.98M20.24M30.17M9.66M-107.14M44.15M
Nektar Therapeutics Net Cash from (used by) Operating Activities
-73.08M-142M-38.52M-129.75M-113.74M-55.87M39.73M-145.78M146.3M
Increase (Decrease) in Prop Plant And Equipment-11.19M-9.97M-4.09M-10.58M-9.72M-31.45M-20.7M-18.85M-32.79M
Acquisition Disposition of Subsidiaires-------4.44M114.83M-
Increase (Decrease) in Investments-28.14M-27.59M54M148.6M-102.23M48.16M-123.89M178.67M0.14M
Other Cash Inflow (Outflow) from Investment Activities25M---25M-----
Nektar Therapeutics Net Cash from (used by) Invesment Activities
-14.33M-37.57M49.9M113.02M-111.95M16.71M-149.03M274.65M-32.65M
Issuance (Purchase) of Equity Shares32.2M163.52M8.2M4.11M224.31M8.89M4.82M0.38M3.78M
Issuance (Repayment) of Debt Securities98.57M-3.53M-2.99M-96.9M-1.97M-1.35M-1.28M-50.12M-105.54M
Increase (Decrease) in Bank & Other Borrowings---------
Payment of Dividends & Other Cash Distributions---------
Other Cash from (used by) Financing Activities
Nektar Therapeutics Net Cash from (used by) Financing Activities
130.78M152.98M2.21M26.8M222.33M7.53M3.53M-49.74M-101.76M
Effect of Exchange Rate Changes on Cash-0.15M-0.1M0.03M0.06M0.91M-0.21M-0.22M0.16M0.65M
Nektar Therapeutics Net Change in Cash & Cash Equivalents
43.2M-26.7M13.63M10.12M-2.44M-31.84M-105.98M79.29M12.53M
Cash & Equivalents at Beginning of Year12.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M63.76M
Cash & Equivalents at Year End55.57M12.36M39.06M25.43M15.31M17.75M49.59M155.58M76.29M
All figures in USD. M: Millions of USD, B: Billions of USD.
View Previous Years
View Next Years
Get Cash flow for another ticker

1:22
NKTR
The statement of cash flows comprises of cash flow from financing, cash flow from operations and cash flow from investing activities. All the three can have an impact on the stock price. The Nektar Therapeutics stock price history and Nektar Therapeutics stock comparison chart inevitably reflect its cash flow situation.
  • Nektar Therapeutics has cash of $55.57M on hand. A healthy amount of cash on hand is necessary for any company. Cash has an opportunity cost associated with it, and too much cash in bank may mean that the firm has no or limited growth plans. Hence its important to track the Net Change in Cash and Cash Equivalents along with the Nektar Therapeutics stock price.
  • Cash Flow from operating activities: Operating activities include the core business activities. This line item refers to the cash generated from the same and stood at a negative value of $-73.08M for NKTR.
  • Growth companies (typically most tech companies) spend heavily  on investing activities and this figure was negative at $-14.33M for NKTR stock. Sometimes a company might have a negative overall cash flow which may not be really bad if it is due to investment expenses. Hence it is important to check the cash flow from investment activities.
  • Cash Flow from financing activities: The cash inflow/outflow from financing activities was $130.78M for Nektar Therapeutics. The money accounted for under this head comes from external sources which includes lenders, investors and shareholders. Positive cash flow is generated when the company gets cash because of issuance of stocks or bonds. Similarly negative cash flow is generated when shares are repurchased, dividend payments are made, and loans or interest on loans are paid back.
.

Key Financial Ratios For Nektar Therapeutics Cash Flow

FCF margin
-0.77